You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,840,866


✉ Email this page to a colleague

« Back to Dashboard


Title:Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s): Kung; Hank F. (Springfield, PA), Kung; Mei-Ping (Wynnewood, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Filing Date:Jan 07, 2013
Application Number:13/735,609
Claims:1. A compound of Formula I ##STR00039## or a pharmaceutically acceptable salt thereof; wherein n is an integer from one to six; A.sub.4 is N; A.sub.1, A.sub.2, A.sub.3, and A.sub.5 are independently --CH, or --CR.sup.2, as permitted; R.sup.1 is: --(CH.sub.2).sub.pNR.sup.aR.sup.b, wherein R.sup.a and R.sup.b are independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl hydroxy(C.sub.1-4)alkyl or halo(C.sub.1-4)alkyl, and p is an integer from 0 to 5; hydroxy, (C.sub.1-4) alkoxy, hydroxy(C.sub.1-4)alkyl, halogen, cyano, nitro, (C.sub.1-4)alkyl, halo(C.sub.1-4)alkyl, formyl, --NHCO(C.sub.1-4 alkyl), or --OCO(C.sub.1-4 alkyl); R.sup.2 is: ##STR00040## wherein, q is an integer from 1 to 10, Rx and Ry are hydrogen, hydroxy or C.sub.1-4 alkyl; t is 0, 1, 2 or 3; Z is hydroxy, halogen, benzoyloxy substituted with halogen, benzyloxy substituted with halogen, phenyl(C.sub.1-4)alkyl substituted with halogen, aryloxy substituted with halogen, or a C.sub.6-10 aryl substituted with halogen; and R.sup.30, R.sup.31, R.sup.32 and R.sup.33 are in each instance independently hydrogen, hydroxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, or hydroxy(C.sub.1-4alkyl; ##STR00041## wherein Rx and Ry are hydrogen, hydroxy or C.sub.1-4 alkyl; t is 0, 1, 2 or 3; Y is halogen, benzoyloxy substituted with halogen, phenyl(C.sub.1-4)alkyl substituted with halogen, aryloxy substituted with halogen, or C.sub.6-10 aryl substituted with halogen; U is hydrogen, hydroxy, halogen, benzoyloxy substituted with halogen, phenyl(C.sub.1-4)alkyl substituted with halogen, aryloxy substituted with halogen, or C.sub.6-10 aryl substituted with halogen; and R.sup.34, R.sup.35, R.sup.36, R.sup.37, R.sup.38, R.sup.39 and R.sup.40 are in each instance independently hydrogen, halogen, hydroxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, or hydroxy(C.sub.1-4)alkyl; iii. NR'R'', wherein at least one of R' and R'' is (CH.sub.2).sub.dX, where X is halogen, and d is an integer from 1 to 4; the other of R' and R'' is hydrogen, C.sub.1-4-alkyl, halo(C.sub.1-4)alkyl, or hydroxy(C.sub.1-4alkyl; iv. halo(C.sub.1-4)alkyl; or v. an ether having the structure: [halo(C.sub.1-4)alkyl-O--(C.sub.1-4)alkyl]-; and R.sup.7 and R.sup.8 are each hydrogen.

2. The compound of claim 1 wherein R.sup.1 is hydroxy or --(CH.sub.2).sub.pNR.sup.aR.sup.b, wherein p is an integer from 0 to 5, and R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, or (CH.sub.2).sub.dX, where X is halogen, and d is an integer from 1 to 4, R.sup.2 is ##STR00042## wherein t is 0; ##STR00043## wherein t is 0; iii. NR'R''; iv. halo(C.sub.1-4)alkyl; or v. an ether having the structure: [halo(C.sub.1-4)alkyl-O--(C.sub.1-4)alkyl]-.

3. The compound of claim 1, wherein n is one.

4. The compound of claim 1, wherein at least one halogen is a radiohalogen.

5. The compound of claim 1, wherein at least one halogen is I, .sup.123I, .sup.125I, .sup.131I, .sup.76Br, .sup.77Br, F or .sup.18F.

6. The compound of claim 5, wherein R.sup.1 is --(CH.sub.2).sub.pNR.sup.aR.sup.b, wherein R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, or t-butyl, isobutyl and p is 0.

7. The compound of claim 6, wherein R.sup.2 is ##STR00044## wherein t is 0.

8. The compound of claim 7, wherein q is an integer from 1 to 5.

9. The compound of claim 8, wherein R.sup.30, R.sup.31, R.sup.32 and R.sup.33 are each hydrogen.

10. The compound of claim 9, having the formula: ##STR00045## wherein, R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl and Z is I, .sup.123I, .sup.125I, .sup.131I, Br, .sup.76Br, .sup.77Br, F or .sup.18F.

11. The compound of claim 6, wherein R.sup.2 is ##STR00046## wherein t is 0 and Z is hydroxy.

12. The compound of claim 11, wherein q is an integer from 1 to 5.

13. The compound of claim 12, wherein R.sup.30, R.sup.31, R.sup.32 and R.sup.33 are each hydrogen, and q is 1, 2 or 3.

14. The compound of claim 6, wherein R.sup.2 is ##STR00047## wherein t is 0 and U is hydroxy.

15. The compound of claim 14, wherein R.sup.34, R.sup.35, R.sup.36 and R.sup.37, R.sup.38, R.sup.39 and R.sup.40 are each hydrogen.

16. The compound of claim 14, having the formula: ##STR00048## wherein R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl.

17. A composition comprising a compound according to claim 1 wherein said compound comprises a .sup.11C isotope, said isotope present in an amount above natural abundance, and said compound containing said .sup.11C isotope having a specific activity above background level.

18. A compound of Formula Ia: ##STR00049## wherein A.sub.4 is N and A.sub.1, A.sub.2, A.sub.3, and A.sub.5 are --CH or C--(O--CH.sub.2CH.sub.2).sub.qX as permitted; q is an integer from 1 to 10; R' and R'' are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl and X is a radiohalogen.

19. The compound of claim 18, wherein one of R' and R'' is hydrogen, the other is ethyl, propyl, isopropyl, butyl, t-butyl or isobutyl.

20. A pharmaceutical composition comprising a compound of any one of claim 1 or 18 and a pharmaceutically acceptable carrier or diluent.

21. A diagnostic composition for imaging amyloid deposits, comprising a radiolabeled compound of any one of claim 1 or 18 and a pharmaceutically acceptable carrier or diluent.

22. A method of imaging amyloid deposits in a mammal, comprising: a. introducing into the mammal a detectable quantity of a diagnostic composition of claim 21; b. allowing sufficient time for the labeled compound to be associated with amyloid deposits; and c. detecting the labeled compound associated with one or more amyloid deposits.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.